[go: up one dir, main page]

EA201300610A1 - Хиназолинкарбоксамидазетидины - Google Patents

Хиназолинкарбоксамидазетидины

Info

Publication number
EA201300610A1
EA201300610A1 EA201300610A EA201300610A EA201300610A1 EA 201300610 A1 EA201300610 A1 EA 201300610A1 EA 201300610 A EA201300610 A EA 201300610A EA 201300610 A EA201300610 A EA 201300610A EA 201300610 A1 EA201300610 A1 EA 201300610A1
Authority
EA
Eurasian Patent Office
Prior art keywords
hinazolincarboxamidasetidine
carboxamidazetidine
quinazoline
formula
accordance
Prior art date
Application number
EA201300610A
Other languages
English (en)
Other versions
EA023821B1 (ru
Inventor
Бейярд Р. Хак
Рейнальдо Джонс
Юфан Сяо
Константин Неагу
Доналд Бэнкстон
Андреас Гоутопоулос
Original Assignee
Мерк Патент Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мерк Патент Гмбх filed Critical Мерк Патент Гмбх
Publication of EA201300610A1 publication Critical patent/EA201300610A1/ru
Publication of EA023821B1 publication Critical patent/EA023821B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Изобретение обеспечивает новые соединения хиназолинкарбоксамидазетидина в соответствии с формулой (I)и их применение для лечения гиперпролиферативных заболеваний, таких как злокачественное новообразование.
EA201300610A 2010-11-24 2011-11-11 Хиназолинкарбоксамидазетидины, их применение в лечении гиперпролиферативных заболеваний и содержащие их композиции EA023821B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41713110P 2010-11-24 2010-11-24
PCT/EP2011/005691 WO2012069146A1 (en) 2010-11-24 2011-11-11 Quinazoline carboxamide azetidines

Publications (2)

Publication Number Publication Date
EA201300610A1 true EA201300610A1 (ru) 2013-12-30
EA023821B1 EA023821B1 (ru) 2016-07-29

Family

ID=45001695

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201300610A EA023821B1 (ru) 2010-11-24 2011-11-11 Хиназолинкарбоксамидазетидины, их применение в лечении гиперпролиферативных заболеваний и содержащие их композиции

Country Status (30)

Country Link
US (1) US8946247B2 (ru)
EP (1) EP2643313B9 (ru)
JP (1) JP5897590B2 (ru)
KR (1) KR101894116B1 (ru)
CN (1) CN103228649B (ru)
AR (1) AR093725A1 (ru)
AU (1) AU2011334173B2 (ru)
BR (1) BR112013012488B1 (ru)
CA (1) CA2818706C (ru)
CL (1) CL2013001459A1 (ru)
CO (1) CO6721019A2 (ru)
DK (1) DK2643313T3 (ru)
EA (1) EA023821B1 (ru)
ES (1) ES2594404T3 (ru)
HR (1) HRP20161183T1 (ru)
HU (1) HUE028967T2 (ru)
IL (1) IL226233A (ru)
LT (1) LT2643313T (ru)
MX (1) MX355325B (ru)
MY (1) MY186456A (ru)
NZ (1) NZ612224A (ru)
PE (1) PE20140966A1 (ru)
PL (1) PL2643313T3 (ru)
PT (1) PT2643313T (ru)
RS (1) RS55204B1 (ru)
SG (1) SG190318A1 (ru)
SI (1) SI2643313T1 (ru)
UA (1) UA112167C2 (ru)
WO (1) WO2012069146A1 (ru)
ZA (1) ZA201304637B (ru)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX346095B (es) 2011-09-12 2017-03-07 Merck Patent Gmbh Nuevas imidazol-aminas como moduladores de la actividad de cinasas.
CN106946796B (zh) 2011-09-12 2020-05-08 默克专利有限公司 用作激酶活性调节剂的氨基嘧啶衍生物
WO2014078634A1 (en) 2012-11-16 2014-05-22 Merck Patent Gmbh Novel imidazol-piperidinyl derivatives as modulators of kinase activity
AR093512A1 (es) 2012-11-16 2015-06-10 Merck Patent Gmbh Derivados heterociclicos como moduladores de la actividad de cinasas
PE20151782A1 (es) * 2012-11-29 2015-12-02 Merck Patent Gmbh Derivados de azaquinolin-carboxamida
SG10201900954SA (en) 2013-03-11 2019-02-27 Merck Patent Gmbh Heterocycles as Modulators of Kinase Activity
US9980966B2 (en) * 2014-04-03 2018-05-29 Merck Patent Gmbh Combinations of cancer therapeutics
AU2015360006B2 (en) * 2014-12-11 2020-07-16 Merck Patent Gmbh Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with a quinazoline derivative
EP3416641A1 (en) * 2016-02-16 2018-12-26 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Modulators of ccr9 for treating tumor resistance to immune responses
EP3416640A1 (en) * 2016-02-16 2018-12-26 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Modulators of tumor immune resistance for the treatment of cancer
US20210017174A1 (en) 2018-03-07 2021-01-21 Bayer Aktiengesellschaft Identification and use of erk5 inhibitor
WO2021094209A1 (en) 2019-11-12 2021-05-20 Bayer Aktiengesellschaft Substituted pyrrolo triazine carboxamide derivatives as prostaglandin ep3 receptor antagonists
WO2022101459A1 (en) 2020-11-16 2022-05-19 Merck Patent Gmbh Kinase inhibitor combinations for cancer treatment
CN116490187A (zh) * 2020-11-16 2023-07-25 默克专利股份公司 用于癌症治疗的激酶抑制剂组合
US11866421B2 (en) * 2021-05-31 2024-01-09 Epigen Biosciences, Inc. Pyrimidine and pyridine amine compounds and usage thereof in disease treatment
CA3262155A1 (en) 2022-08-11 2024-02-15 Evexta Bio COMPOUNDS FOR CANCER TREATMENT
WO2025168601A1 (en) 2024-02-05 2025-08-14 Evexta Bio Quinazoline carboxamide azetidine compounds for use in treating hormone dependent diseases

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200306819A (en) 2002-01-25 2003-12-01 Vertex Pharma Indazole compounds useful as protein kinase inhibitors
AU2003252314A1 (en) * 2002-08-09 2004-02-25 Kyorin Pharmaceutical Co., Ltd. 4-substituted quinazoline-8-carboxyamide derivative and pharmaceutically acceptable addition salt thereof
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
WO2004092154A1 (en) 2003-04-03 2004-10-28 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
US7189729B2 (en) 2003-09-30 2007-03-13 Irm Llc Methods and compositions as protein kinase inhibitors
WO2005039506A2 (en) 2003-10-24 2005-05-06 Exelixis, Inc. P70s6 kinase modulators and method of use
BRPI0416801A (pt) 2003-11-21 2007-01-09 Novartis Ag derivados de 1h-imidazoquinolina como inibidores de proteìna sinase
RU2006124421A (ru) 2003-12-09 2008-01-20 ПРАВИТЕЛЬСТВО СОЕДИНЕННЫХ ШТАТОВ АМЕРИКИ, ПРЕДСТАВЛЕННОЕ СЕКРЕТАРЕМ ДЕПАРТАМЕНТА ЗДРАВООХРАНЕНИЯ И СЛУЖБЫ ДЛЯ ЛЮДЕЙ, УС Национальный Институт здравоохранени , Ведомство по передаче технологий (US) Способ подавления ответной иммунной реакции или лечения пролиферативного нарушения
JP5213229B2 (ja) 2004-04-23 2013-06-19 エグゼリクシス， インコーポレイテッド キナーゼ調節因子および使用方法
ATE543821T1 (de) 2004-12-28 2012-02-15 Exelixis Inc Ä1h-pyrazoloä3,4-düpyrimidin-4-ylü-piperidin- oder piperazinverbindungen als serin-threonin- kinasemodulatoren (p70s6k, atk1 und atk2) zur behandlung von immunologischen, entzündlichen und proliferativen erkrankungen
GB0501999D0 (en) 2005-02-01 2005-03-09 Sentinel Oncology Ltd Pharmaceutical compounds
WO2006136821A1 (en) 2005-06-22 2006-12-28 Astex Therapeutics Limited Pharmaceutical compounds
UA99284C2 (ru) 2007-05-11 2012-08-10 Елі Ліллі Енд Компані ИНГИБИТОРЫ р70 S6-КИНАЗЫ
DE102007032739A1 (de) * 2007-07-13 2009-01-15 Merck Patent Gmbh Chinazolinamidderivate
CA2751886C (en) 2009-02-11 2017-08-29 Merck Patent Gmbh Novel amino azaheterocyclic carboxamides
UA110113C2 (xx) * 2010-07-29 2015-11-25 Біциклічні азагетероциклічні карбоксаміди
EP2598497B1 (en) * 2010-07-29 2019-03-06 Merck Patent GmbH Cyclic amine azaheterocyclic carboxamides

Also Published As

Publication number Publication date
CN103228649A (zh) 2013-07-31
UA112167C2 (uk) 2016-08-10
BR112013012488B1 (pt) 2021-08-31
AU2011334173B2 (en) 2015-07-16
US8946247B2 (en) 2015-02-03
ZA201304637B (en) 2014-03-26
IL226233A0 (en) 2013-07-31
SI2643313T1 (sl) 2016-11-30
HRP20161183T1 (hr) 2016-11-04
MX2013005751A (es) 2013-08-01
MY186456A (en) 2021-07-22
CA2818706A1 (en) 2012-05-31
JP5897590B2 (ja) 2016-03-30
PT2643313T (pt) 2016-10-11
MX355325B (es) 2018-04-16
DK2643313T3 (en) 2016-10-24
AU2011334173A1 (en) 2013-05-02
NZ612224A (en) 2015-01-30
WO2012069146A1 (en) 2012-05-31
BR112013012488A2 (pt) 2016-07-19
PL2643313T3 (pl) 2017-03-31
CO6721019A2 (es) 2013-07-31
LT2643313T (lt) 2016-10-25
EP2643313B1 (en) 2016-06-29
US20130252942A1 (en) 2013-09-26
EP2643313B9 (en) 2017-02-22
RS55204B1 (sr) 2017-01-31
KR101894116B1 (ko) 2018-08-31
HUE028967T2 (en) 2017-01-30
SG190318A1 (en) 2013-06-28
EP2643313A1 (en) 2013-10-02
IL226233A (en) 2017-07-31
KR20130130753A (ko) 2013-12-02
PE20140966A1 (es) 2014-08-06
JP2013544257A (ja) 2013-12-12
HK1188444A1 (zh) 2014-05-02
CL2013001459A1 (es) 2013-12-27
CN103228649B (zh) 2015-11-25
EA023821B1 (ru) 2016-07-29
ES2594404T3 (es) 2016-12-20
CA2818706C (en) 2019-07-23
AR093725A1 (es) 2015-06-24

Similar Documents

Publication Publication Date Title
EA201300610A1 (ru) Хиназолинкарбоксамидазетидины
EA201200218A1 (ru) Новые бициклические соединения мочевины
EA201101182A1 (ru) Новые аминоазагетероциклические карбоксамиды
EA201200247A1 (ru) Новые азагетероциклические соединения
EA201300186A1 (ru) Бициклические азагетероциклические карбоксамиды
EA201400338A1 (ru) Производные аминопиримидина для применения в качестве модуляторов киназной активности
EA201400339A1 (ru) Новые имидазоламины в качестве модуляторов киназной активности
EA201100296A1 (ru) Новые фениламино-изоникотинамидные соединения
EA201171367A1 (ru) Винилиндазолильные соединения
EA201391626A1 (ru) Соединения для ингибирования клеточной пролиферации в egfr-стимулированных типах рака
EA201400412A1 (ru) ЗАМЕЩЕННЫЕ БЕНЗИЛИНДАЗОЛЫ ДЛЯ ПРИМЕНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ Bub1 КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ ГИПЕРПРОЛИФЕРАТИВНЫХ ЗАБОЛЕВАНИЙ
EA201270257A1 (ru) Производные n1-сульфонил-5-фторпиримидинона
EA201400178A1 (ru) Лечение рака молочной железы
EA201290744A1 (ru) Имидазо[1,2-b][1,2,4]триазины в качестве c-met ингибиторов
EA201290642A1 (ru) Соединения и способы
EA201500314A1 (ru) Лекарственные формы энзалутамида
EA201290909A1 (ru) Химические соединения
EA201270254A1 (ru) Производные 5-фторпиримидинона
UA108101C2 (xx) Похідні n3-заміщених n1-сульфоніл-5-фторпіримідинонів
EA201590987A1 (ru) Соединения и способы их применения
EA201692166A1 (ru) Гетероциклические ингибиторы глютаминазы
EA201200473A1 (ru) Замещенные (гетероарилметил)тиогидантоины
EA201270619A1 (ru) Применение бетанехола для лечения ксеростомии
EA201590997A1 (ru) Соединения и способы их применения
EA201390274A1 (ru) Борсодержащие малые молекулы

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM